0001209191-21-056057.txt : 20210914 0001209191-21-056057.hdr.sgml : 20210914 20210914192946 ACCESSION NUMBER: 0001209191-21-056057 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210914 FILED AS OF DATE: 20210914 DATE AS OF CHANGE: 20210914 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Burgess Paul D. CENTRAL INDEX KEY: 0001744627 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38550 FILM NUMBER: 211253769 MAIL ADDRESS: STREET 1: C/O TRANSLATE BIO, INC. STREET 2: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Translate Bio, Inc. CENTRAL INDEX KEY: 0001693415 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 611807780 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-945-7361 MAIL ADDRESS: STREET 1: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: RaNA Therapeutics, Inc. DATE OF NAME CHANGE: 20161228 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-09-14 0 0001693415 Translate Bio, Inc. TBIO 0001744627 Burgess Paul D. C/O TRANSLATE BIO, INC. 29 HARTWELL AVE LEXINGTON MA 02421 0 1 0 1 Chief Operating Officer, CLO Secretary Common Stock 2021-09-14 4 S 0 71833 38.00 D 0 D Stock Option (right to buy) 7.39 2021-09-14 4 S 0 219652 0.00 D 2027-12-21 Common Stock 219652 0 D Stock Option (right to buy) 8.34 2021-09-14 4 S 0 69953 0.00 D 2028-03-06 Common Stock 69953 0 D Stock Option (right to buy) 7.95 2021-09-14 4 S 0 150000 0.00 D 2029-03-07 Common Stock 150000 0 D Stock Option (right to buy) 7.66 2021-09-14 4 S 0 150000 0.00 D 2030-03-02 Common Stock 150000 0 D Stock Option (right to buy) 23.82 2021-09-14 4 S 0 90000 0.00 D 2031-03-08 Common Stock 90000 0 D As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. This option was granted on December 22, 2017. The shares underlying the option became fully vested on March 9, 2021. This option was granted on March 7, 2018. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 7, 2019 and the remainder vesting in equal monthly installments through March 7, 2022. This option was granted on March 8, 2019. This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023. This option was granted on March 3, 2020. This option will vest as to 25% of the shares on December 11, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through December 11, 2023. This option was granted on March 9, 2021. This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares though March 9, 2025. /s/ Paul D. Burgess 2021-09-14